- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00960895
Pulmonary Hypertension in Lymphangioleiomyomatosis (LAM-PH)
October 26, 2011 updated by: Vincent COTTIN, Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Observational Study of Patients With Lymphangioleiomyomatosis and Pulmonary Hypertension
This is a descriptive study of patients with Lymphangioleiomyomatosis and precapillary pulmonary hypertension.
Study Overview
Status
Completed
Conditions
Detailed Description
Descriptive study of patients with Lymphangioleiomyomatosis and precapillary pulmonary hypertension This will include modality of diagnosis of lLymphangioleiomyomatosis, results of right-sided heart catheterization, and pulmonary function tests
Study Type
Observational
Enrollment (Actual)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
University of Lyon
-
Lyon, University of Lyon, France, 69677
- Louis Pradel Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Lymphangioleiomyomatosis, either sporadic or associated with tuberous sclerosis Precapillary pulmonary hypertension, as defined by right-sided heart catheterization (mean pulmonary artery pressure higher than 25 mmHg, wedge capillary pulmonary pressure less than 15 mmHg, pulmonary vascular resistance higher than 3 Wood units)
Description
Inclusion Criteria:
- Lymphangioleiomyomatosis (definite or probable), either sporadic or associated with tuberous sclerosis
- Precapillary pulmonary hypertension, as defined by right-sided heart catheterization (mean pulmonary artery pressure higher than 25 mmHg, wedge capillary pulmonary pressure less than 15 mmHg, pulmonary vascular resistance higher than 3 Wood units)
Exclusion Criteria:
- Post capillary pulmonary hypertension
- Other identifiable causes of pulmonary hypertension (ex: thromboembolic disease)
- Not willing to participate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Vincent Cottin, MD, University of Lyon
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (Actual)
December 1, 2009
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
August 17, 2009
First Submitted That Met QC Criteria
August 17, 2009
First Posted (Estimate)
August 18, 2009
Study Record Updates
Last Update Posted (Estimate)
October 27, 2011
Last Update Submitted That Met QC Criteria
October 26, 2011
Last Verified
October 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lung Diseases
- Lymphangiomyoma
- Lymphatic Vessel Tumors
- Perivascular Epithelioid Cell Neoplasms
- Hypertension
- Hypertension, Pulmonary
- Lymphangioleiomyomatosis
Other Study ID Numbers
- GERMOP-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Guangdong Provincial People's HospitalRecruitingIdiopathic Pulmonary HypertensionChina
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Poitiers University HospitalNot yet recruitingChronic Thromboembolic Pulmonary Hypertension (CTEPH) | Pulmonary Arterial Hypertension (PAH)
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
BayerCompletedPrimary HypertensionChina
-
Regeneron PharmaceuticalsRecruitingPulmonary Arterial Hypertension (PAH)United States, United Kingdom, Latvia, South Korea